By the end of this topic, the student should be able to:
When most people think of opioids, they usually think of medicines or unregulated drugs. In fact, the human body produces more than 20 opioids as part of its natural neuroregulation processes. Opioids produced in the body are considered endogenous opioids. This is in contrast to exogenous opioids, which are opioids one might use for medicinal or other purposes. Exogenous opioids are either plant-derived or synthetic.
Plant-derived or synthetic opioids are all large organic molecules; however, endogenous opioids are small peptides (i.e., made up of amino acids). These opioid peptides are derived from larger proteins (preproopiomelanocortin, preproenkephalin, and preprodynorphin).
There are three main types of endogenous opioid peptides:
Both endogenous opioid peptides and exogenous opioids (medicines, drugs) act primarily via three opioid receptors:
Although all three opioid receptors are expressed throughout the body and across many systems, mu opioid receptors are sometimes referred to as supra-spinal because they mediate many of the effects in the brain, including acting in the reward system (i.e., limbic system).
Most opioids are considered full agonists, which means they can maximally activate opioid receptors. Some are partial agonists that only partially activate receptors.
Full agonists examples:
Partial agonist example:
Opioids are used primarily for their pain-relieving (analgesic) effects for moderate to severe acute pain due to a variety of causes.
Pain is signaled to the brain via activation of the ascending pain pathway.
The body (including the opioid system) is able to dampen pain by activating the descending inhibitory pathway. This pathway works from the brain down to the spinal cord, so works in the opposite direction of the ascending pain pathway. The pathway inhibits the ascending pain signal.
Opioids are used primarily for their analgesic pain-relieving (analgesic) effects for moderate to severe acute pain from a variety of causes.
Opioids relieve pain by:
Less commonly, opioids are used to suppress severe cough and to treat diarrhea, and they are used in palliative care for dyspnea (difficult or laboured breathing).
Opioids are also used in combination with other drugs in anesthesia for surgeries and medical procedures.
Adverse effects of short-term opioid use may include sedation, sleepiness, nausea and vomiting, constipation, itchiness, and others. See Module 8, Topic B for more information.
The most serious adverse effect, respiratory depression, and its reversal by naloxone are discussed in Module 8, Topic E.
Although opioids are used for a wide variety of acute pain, their use and effectiveness for most types of chronic pain are controversial.
In addition to the adverse effects of opioids associated with short-term use, long-term use of opioids can cause:
Long-term opioid use is also linked to
Drug interactions can be classified into types: pharmacokinetic, pharmacologic/pharmacodynamic, and physiological.
Definition
If a pharmacokinetic drug interaction increases the level of opioids, a person may experience increased or more intense adverse effects, including the possibility of respiratory depression.
If a pharmacokinetic drug interaction decreases the level of opioids, a person may experience reduced pain control or withdrawal symptoms.
Methadone is metabolized by an enzyme in the liver called CYP3A4.
A pharmacologic/pharmacodynamic drug interaction occurs when two drugs act on the same receptor.
Morphine activates opioid receptors and naloxone blocks opioid receptors.
Physiological drug interactions occur when two drugs have similar or opposing effects on the body. For example, one drug increases blood pressure, and a second drug decreases blood pressure—these two drugs have an opposing physiological effect.
For opioids, the sedative/CNS depressant properties can combine with those effects caused by other CNS depressants, including alcohol, benzodiazepines, and barbiturates, that also depress respiration.
Often, CNS depressants work together synergistically to cause sedation or respiratory depression.
Like all systems in the body, the opioid system is constantly fine-tuned. If the system becomes over-activated, the body takes steps to reduce this activity, and if the system is downregulated, the body takes steps to increase activity.
Definition
When exogenous opioids are taken, the endogenous opioid system detects the over-activity they cause, and reacts by reducing activity. It does this by reducing production of endogenous opioid peptides and reducing the number of opioid receptors, among other things.
If opioid use is stopped, the opioid system returns back to its original state over time.
With continued use, the body’s opioid system activity may be further and further impaired. Eventually, endogenous opioid system activity is reduced to the point that the body becomes reliant on continued exogenous opioids—termed opioid dependence.
Once a person is dependent on opioids, they will experience symptoms of opioid withdrawal if they stop taking opioids. How fast these withdrawal symptoms start depends on the half-life of the opioid used:
Tzido/iStock
When these symptoms occur, they are readily reversed by additional doses of an opioid. Withdrawal symptoms can be minimized by tapering the dose of the opioid.
Withdrawal severity is assessed clinically using the Clinical Opiate Withdrawal Scale (COWS) (Wesson & Ling, 2003).
Why might switching from methadone to buprenorphine cause withdrawal symptoms?
Feedback
Methadone is a full (100 percent) opioid receptor agonist. Buprenorphine is a partial agonist. Buprenorphine activates opioid receptors but only partially (let’s assume 50 percent). So, if someone were to take buprenorphine alone, their opioid receptor activation would increase from baseline (0) to 50 percent. However, if a full agonist is present, buprenorphine reduces opioid receptor activation (let’s assume from 100 percent towards 50 percent) and can precipitate withdrawal symptoms. Thus, careful dosing, timing, and consideration are required when switching from methadone to buprenorphine.
Brunton, L. L., Hilal-Dandan, R., & Knollmann, B. C. (2018). Goodman and Gilman’s the pharmacological basis of therapeutics (13th ed.). McGraw-Hill Education.
DiPiro, J. T., Yee, G. C. L., Posey, M., Haines, S. T., Nolin, T. D., & Ellingrod, V. (2019). Pharmacotherapy: A pathophysiologic approach (11th ed.). McGraw-Hill Education.
Katzung, B. G. (2018). Basic and clinical pharmacology (14th ed.). McGraw-Hill Education.
McCance-Katz, E. F., Sullivan, L., & Nallani, S. (2010). Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: A review. American Journal on Addictions, 19, 4–16.
Wesson, D. R., & Ling, W. (2003). The Clinical Opiate Withdrawal Scale (COWS). Journal of Psychoactive Drugs, 35, 253–259.